Therefore, our study demonstrated that CDKN1A may serve as an important biomarker for predicting ITP patients’ response to Eltrombopag treatment, further highlighting its potential and exceptional performance in the diagnosis of ITP. The gene discussed is CDKN1A; the disease is autoimmune thrombocytopenic purpura.